IL-17 enhances tumor development in carcinogen-induced skin cancer

Cancer Research

Volumn 70, Issue 24, 2010, Pages 10112-10120

  Wang, Lin ^a   Yi, Tangsheng ^a   Zhang, Wang ^a   Pardoll, Drew M ^b   Yu, Hua ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOGEN; CHEMOKINE; INTERLEUKIN 17; STAT3 PROTEIN;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER MODEL; CARCINOGENESIS; CELL INFILTRATION; CELL PROLIFERATION; CONTROLLED STUDY; EPIDERMIS CELL; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE INACTIVATION; HYPERPLASIA; INFLAMMATION; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SKIN CANCER; TUMOR MICROENVIRONMENT;

ANILINE COMPOUNDS; ANIMALS; ANTIGENS, CD11B; CARCINOGENS; CELL GROWTH PROCESSES; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; INTERFERON-GAMMA; INTERLEUKIN-17; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; SKIN; SKIN NEOPLASMS; STAT3 TRANSCRIPTION FACTOR; TETRADECANOYLPHORBOL ACETATE; TUMOR MICROENVIRONMENT;

EID: 78650359166     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-0775     Document Type: Article

References (38)

1. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454:436-44.
2. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006;441:431-6.
3. Bromberg J. Stat proteins and oncogenesis. J Clin Investig 2002;109:1139-42.
4. Kortylewski M, Kujawski M, Wang T, et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nature Med 2005;11:1314-21.
5. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev 2007;7:41-51.
6. Kortylewski M, Xin H, Kujawski M, et al. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell 2009;15:114-23.
7. He D, Li H, Yusuf N, et al. IL-17 Promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells. J Immunol 2010;184:2281-8.
8. Kaplan DH, Shankaran V, Dighe AS, et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice.Proc Natl Acad Sci U S A 1998;95:7556-61.
9. Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 2009;206:1457-64.
10. Xiao M, Wang C, Zhang J, Li Z, Zhao X, Qin Z. IFNgamma promotes papilloma development by up-regulating Th17-associated inflammation. Cancer Res 2009;69:2010-7.
11. + T-cells in 7,12-dimethylbenz(a)anthracene cutaneous carcinogenesis. Cancer Res 2008;68:3924-30.
12. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev 2003;3:133-46.
13. Agnello D, Lankford CS, Bream J, et al. Cytokines and transcription factors that regulate T helper cell differentiation: new players and new insights. J Clin Immunol 2003;23:147-61.
14. Wu S, Rhee KJ, Albesiano E, et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med 2009;15:1016-22.
15. Chen Z, Laurence A, Kanno Y, et al. Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells. Proc Natl Acad Sci U S A 2006;103:8137-42.
16. Chen Z, O'Shea JJ. Th17 cells: a new fate for differentiating helper T cells. Immunol Res 2008;41:87-102.
17. Kryczek I, Wei S, Szeliga W, Vatan L, Zou W. Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood 2009; 114:357-9.
18. Martin-Orozco N, Muranski P, Chung Y, et al. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 2009;31:787-98.
19. +IL-17-producing T cells in ovarian cancer. Proc Natl Acad Sci U S A 2008;105:15505-10.
20. Zhang B, Rong G, Wei H, et al. The prevalence of Th17 cells in patients with gastric cancer. Biochem Biophys Res Commun 2008;374:533-7.
21. Zhang JP, Yan J, Xu J, et al. Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol 2009;50:980-9.
22. Ehrenreiter K, Kern F, Velamoor V, et al. Raf-1 addiction in Ras-induced skin carcinogenesis. Cancer Cell 2009;16:149-60.
23. Langowski JL, Zhang X, Wu L, et al. IL-23 promotes tumour incidence and growth. Nature 2006;442:461-5.
24. Nakae S, Komiyama Y, Nambu A, et al. Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity 2002;17:375-87.
25. Yi T, Chen Y, Wang L, et al. Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease. Blood 2009;114:3101-12.
26. Chan KS, Sano S, Kiguchi K, et al. Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis.J Clin Investig 2004;114:720-8.
27. Cheng P, Corzo CA, Luetteke N, et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med 2008;205:2235-49.
28. Kujawski M, Kortylewski M, Lee H, Herrmann A, Kay H, Yu H. Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Investig 2008;118:3367-77.
29. Bunt SK, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S. Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J Immunol 2006;176:284-90.
30. Fielding CA, McLoughlin RM, McLeod L, et al. IL-6 regulates neutrophil trafficking during acute inflammation via STAT3. J Immunol 2008;181:2189-95.
31. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009;9:798-809.
32. Ogura H, Murakami M, Okuyama Y, et al. Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction. Immunity 2008;29:628-36.
33. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene 2000;19:2474-88.
34. Hirano T, Ishihara K, Hibi M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 2000;19:2548-56.
35. Moore RJ, Owens DM, Stamp G, et al. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med 1999;5:828-31.
36. Charles KA, Kulbe H, Soper R, et al. The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans.J Clin Investig 2009;119:3011-23.
37. Lee H, Herrmann A, Deng JH, et al. Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell 2009;15:283-93.
38. DeNardo DG, Barreto JB, Andreu P, et al. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 2009;16:91-102.